DexCom (DXCM) Stock Forecast & Price Target

$73.74 +1.40 (+1.94%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$73.35 -0.39 (-0.53%)

As of 05/29/2026 07:58 PM Eastern

Compare

DexCom - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 26 Analyst Ratings

Sell
1

Hold
3

Buy
22

Based on 26 Wall Street analysts who have issued ratings for DexCom in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 1 has given a sell rating, 3 have given a hold rating, 19 have given a buy rating, and 3 have given a strong buy rating for DXCM.

Consensus Price Target

$82.42
11.77% Upside

According to the 26 analysts' twelve-month price targets for DexCom, the average price target is $82.42. The highest price target for DXCM is $102.00, while the lowest price target for DXCM is $64.00. The average price target represents a forecasted upside of 11.77% from the current price of $73.74.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for DXCM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for DexCom and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DXCM Analyst Ratings Over Time

Type	Current Forecast 5/31/25 to 5/31/26	1 Month Ago 5/1/25 to 5/1/26	3 Months Ago 3/2/25 to 3/2/26	1 Year Ago 5/31/24 to 5/31/25
Strong Buy	3 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	19 Buy rating(s)	18 Buy rating(s)	17 Buy rating(s)	14 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$82.42	$86.09	$85.18	$98.32
Forecasted Upside	11.77% Upside	44.57% Upside	15.45% Upside	14.37% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

DXCM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DXCM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

DexCom Stock vs. The Competition

Type	DexCom	Medical Companies	Broader Market
Consensus Rating Score	2.92	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	11.77% Upside	1,738.75% Upside	14.83% Upside
News Sentiment Rating	Positive News See Recent DXCM News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
5/28/2026	Citigroup 4 of 5 stars	Joanne Wuensch 2 of 5 stars	Reiterated Rating	Buy	$79.00 ➝ $84.00	+19.56%
5/18/2026	Canaccord Genuity Group 4 of 5 stars	William Plovanic 3 of 5 stars	Set Target	Buy	$100.00 ➝ $82.00	+26.46%
5/18/2026	Barclays 3 of 5 stars	Matt Miksic 2 of 5 stars	Reiterated Rating	Underweight	$67.00 ➝ $64.00	+3.85%
5/18/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Travis Steed Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$100.00 ➝ $80.00	+24.53%
5/15/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
5/11/2026	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Buy	$77.00	+29.78%
5/1/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$77.00	+25.35%
5/1/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$80.00	+30.94%
5/1/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$75.00	+22.76%
5/1/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$81.00	+31.70%
Your book attached (Ad) Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. Download the Safe Trade Options Formula book for free before access closes
5/1/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joshua Jennings Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$84.00 ➝ $75.00	+22.59%
3/24/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	In-Line ➝ Outperform	$90.00	+36.49%
3/9/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Marie Thibault Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$85.00	+24.82%
3/4/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Sell (D+) ➝ Hold (C-)
2/17/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Newitter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$82.00 ➝ $80.00	+13.14%
2/13/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$93.00 ➝ $85.00	+21.58%
2/5/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt O'Brien Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight
1/12/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Wood Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight
12/16/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Kratky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$92.00	+39.97%
11/7/2025	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steve Silver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$100.00 ➝ $90.00	+63.80%
11/3/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Antalffy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$106.00 ➝ $95.00	+57.21%
10/31/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$90.00 ➝ $75.00	+27.33%
10/31/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$100.00 ➝ $85.00	+49.31%
10/21/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jonathan Block Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$85.00	+24.21%
10/1/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kate McShane Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$104.00 ➝ $89.00	+37.98%
9/8/2025	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steven Lichtman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
3/21/2025	Cfra Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	T. Perez Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold
2/3/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Issie Kirby Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$85.00 ➝ $115.00	+32.44%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 12:40 AM ET.

Should I Buy DexCom Stock? DXCM Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, May 29, 2026. Please send any questions or comments about these DexCom pros and cons to contact@marketbeat.com.

DexCom
Bull Case

Here are some ways that investors could benefit from investing in DexCom, Inc.:

The current stock price is around $85, reflecting a strong interest from analysts who have rated the stock with a consensus of "Moderate Buy."
DexCom, Inc. has shown impressive revenue growth, with quarterly revenue increasing by 15% compared to the same quarter last year, indicating strong demand for its products.
Institutional investors own a significant majority (97.75%) of DexCom, Inc.'s stock, suggesting confidence in the company's long-term prospects.
Recent analyst upgrades, including a target price of $80 from Truist Financial, highlight positive sentiment and potential for price appreciation.
DexCom, Inc. is at the forefront of continuous glucose monitoring technology, providing innovative solutions that enhance diabetes management for patients.

DexCom
Bear Case

Investors should be bearish about investing in DexCom, Inc. for these reasons:

Some analysts have issued lower target prices, with Barclays setting a target of $64, indicating potential concerns about future performance.
Despite revenue growth, the company faces intense competition in the medical device sector, which could impact market share and profitability.
There is a risk of regulatory challenges that could affect the approval and distribution of new products, potentially hindering growth.
Market volatility and economic uncertainties may lead to fluctuations in stock performance, affecting investor confidence.
With a single product line focused on diabetes management, DexCom, Inc. may be vulnerable to market changes and shifts in consumer preferences.

DXCM Forecast - Frequently Asked Questions

According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for DexCom is $82.42, with a high forecast of $102.00 and a low forecast of $64.00.

26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There is currently 1 sell rating, 3 hold ratings, 19 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DXCM shares.

According to analysts, DexCom's stock has a predicted upside of 11.77% based on their 12-month stock forecasts.

Over the previous 90 days, DexCom's stock had 4 upgrades by analysts.

DexCom has been rated by research analysts at Bank of America, Barclays, Benchmark, BTIG Research, Canaccord Genuity Group, Citigroup, Evercore, Mizuho, Raymond James Financial, Robert W. Baird, Sanford C. Bernstein, TD Cowen, Weiss Ratings, and William Blair in the past 90 days.

Analysts like DexCom more than other "medical" companies. The consensus rating for DexCom is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how DXCM compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With DexCom Recommendations

This page (NASDAQ:DXCM) was last updated on 5/31/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DexCom (DXCM) Stock Forecast & Price Target

DexCom - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

DXCM Analyst Ratings Over Time

DXCM Analyst Recommendations By Month

DXCM Price Targets by Month

DexCom Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy DexCom Stock? DXCM Pros and Cons Explained

DexCom
Bull Case

DexCom
Bear Case

DXCM Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With DexCom Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DexCom (DXCM) Stock Forecast & Price Target

DexCom - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

DXCM Analyst Ratings Over Time

DXCM Analyst Recommendations By Month

DXCM Price Targets by Month

DexCom Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy DexCom Stock? DXCM Pros and Cons Explained

DexCom Bull Case

DexCom Bear Case

DXCM Forecast - Frequently Asked Questions

What is DexCom's forecast for 2026?

Should I buy or sell DexCom stock right now?

Does DexCom's stock price have much upside?

Has DexCom been upgraded by Wall Street analysts recently?

What analysts cover DexCom?

Do Wall Street analysts like DexCom more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With DexCom Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

DexCom
Bull Case

DexCom
Bear Case